메뉴 건너뛰기




Volumn 21, Issue 2, 2015, Pages 152-161

Novel therapeutic approaches for haemophilia

Author keywords

Alternate therapy; Aptamer; Haemophilia; Nonsense mutation suppression; Treatment

Indexed keywords

ACE 910; ACTIVATED PROTEIN C; ACTIVATED PROTEIN C INHIBITOR; ALN AT3; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; APTAMER; ARC 19499; ATALUREN; BAX 499; BISPECIFIC ANTIBODY; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10 ANTIBODY; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9A ANTIBODY; FUCOIDIN; HEMATOLOGIC AGENT; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2021; MONOCLONAL ANTIBODY 224AE3; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SMALL INTERFERING RNA; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

EID: 84923107935     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12615     Document Type: Review
Times cited : (15)

References (79)
  • 2
    • 84860351786 scopus 로고    scopus 로고
    • Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database
    • Hemophilia Treatment Center Network (HTCN) Investigators
    • Carpenter SL, Michael Soucie J, Sterner S et al.; Hemophilia Treatment Center Network (HTCN) Investigators. Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database. Haemophilia 2012; 18: e260-5.
    • (2012) Haemophilia , vol.18 , pp. e260-e265
    • Carpenter, S.L.1    Michael Soucie, J.2    Sterner, S.3
  • 3
    • 0033814048 scopus 로고    scopus 로고
    • Transfusion transmitted diseases in haemophilics from western India
    • Ghosh K, Joshi SH, Shetty S et al. Transfusion transmitted diseases in haemophilics from western India. Indian J Med Res 2000; 112: 61-4.
    • (2000) Indian J Med Res , vol.112 , pp. 61-64
    • Ghosh, K.1    Joshi, S.H.2    Shetty, S.3
  • 4
    • 34447250771 scopus 로고    scopus 로고
    • Disability in Indian patients with haemophilia
    • Kar A, Mirkazemi R, Singh P et al. Disability in Indian patients with haemophilia. Haemophilia 2007; 134: 398-404.
    • (2007) Haemophilia , vol.134 , pp. 398-404
    • Kar, A.1    Mirkazemi, R.2    Singh, P.3
  • 5
    • 84898028710 scopus 로고    scopus 로고
    • Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
    • Coyle TE, Reding MT, Lin JC et al. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014; 12: 488-96.
    • (2014) J Thromb Haemost , vol.12 , pp. 488-496
    • Coyle, T.E.1    Reding, M.T.2    Lin, J.C.3
  • 6
    • 84857627016 scopus 로고    scopus 로고
    • PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice
    • Peng A, Kosloski MP, Nakamura G et al. PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice. AAPS J 2012; 14: 35-42.
    • (2012) AAPS J , vol.14 , pp. 35-42
    • Peng, A.1    Kosloski, M.P.2    Nakamura, G.3
  • 7
    • 84873625664 scopus 로고    scopus 로고
    • BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation
    • Turecek PL, Bossard MJ, Graninger M et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie 2012; 32: S29-38.
    • (2012) Hamostaseologie , vol.32 , pp. S29-S38
    • Turecek, P.L.1    Bossard, M.J.2    Graninger, M.3
  • 8
    • 84916232822 scopus 로고    scopus 로고
    • Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study
    • Powell JS, Apte S, Chambost H et al. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol 2014. doi:10.1111/bjh.13112.
    • (2014) Br J Haematol
    • Powell, J.S.1    Apte, S.2    Chambost, H.3
  • 9
    • 84893606658 scopus 로고    scopus 로고
    • Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
    • Zollner S, Schuermann D, Raquet E et al. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). J Thromb Haemost 2014; 12: 220-8.
    • (2014) J Thromb Haemost , vol.12 , pp. 220-228
    • Zollner, S.1    Schuermann, D.2    Raquet, E.3
  • 10
    • 84879460451 scopus 로고    scopus 로고
    • von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo
    • Tang L, Leong L, Sim D et al. von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo. Haemophilia 2013; 19: 539-45.
    • (2013) Haemophilia , vol.19 , pp. 539-545
    • Tang, L.1    Leong, L.2    Sim, D.3
  • 11
    • 13244262642 scopus 로고    scopus 로고
    • Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity
    • Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
    • (2004) J Thromb Haemost , vol.2 , pp. 1700-1708
    • Aledort, L.M.1
  • 12
    • 0345627213 scopus 로고    scopus 로고
    • An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN)
    • van't Veer C, Golden NJ, Kalafatis M et al. An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). Blood 1997; 90: 3067-72.
    • (1997) Blood , vol.90 , pp. 3067-3072
    • van't Veer, C.1    Golden, N.J.2    Kalafatis, M.3
  • 13
    • 34447314172 scopus 로고    scopus 로고
    • Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients
    • Shetty S, Vora S, Kulkarni B et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 2007; 138: 541-4.
    • (2007) Br J Haematol , vol.138 , pp. 541-544
    • Shetty, S.1    Vora, S.2    Kulkarni, B.3
  • 14
    • 48249155867 scopus 로고    scopus 로고
    • Reduced clinical severity in a mutationally well-characterized cohort of severe hemophilia with associated thrombophilia
    • Shetty S, Ghosh K. Reduced clinical severity in a mutationally well-characterized cohort of severe hemophilia with associated thrombophilia. Am J Clin Pathol 2008; 130: 84-7.
    • (2008) Am J Clin Pathol , vol.130 , pp. 84-87
    • Shetty, S.1    Ghosh, K.2
  • 15
    • 34548791196 scopus 로고    scopus 로고
    • Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children - results of a multicenter studies
    • Kurnik K, Kreuz W, Horneff S et al. Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children - results of a multicenter studies. Haematologica 2007; 92: 982-5.
    • (2007) Haematologica , vol.92 , pp. 982-985
    • Kurnik, K.1    Kreuz, W.2    Horneff, S.3
  • 16
    • 84859718853 scopus 로고    scopus 로고
    • Protein C anticoagulant system - anti-inflammatory effects
    • Esmon CT. Protein C anticoagulant system - anti-inflammatory effects. Semin Immunopathol 2012; 34: 127-32.
    • (2012) Semin Immunopathol , vol.34 , pp. 127-132
    • Esmon, C.T.1
  • 17
    • 79955159111 scopus 로고    scopus 로고
    • Protective cross talk between activated protein C and TNF signaling in vascular endothelial cells: implication of EPCR, noncanonical NF-κB, and ERK1/2 MAP kinases
    • Guitton C, Cottereau A, Gérard N et al. Protective cross talk between activated protein C and TNF signaling in vascular endothelial cells: implication of EPCR, noncanonical NF-κB, and ERK1/2 MAP kinases. Am J Physiol Cell Physiol 2011; 300: C833-42.
    • (2011) Am J Physiol Cell Physiol , vol.300 , pp. C833-C842
    • Guitton, C.1    Cottereau, A.2    Gérard, N.3
  • 18
    • 0027438386 scopus 로고
    • Interaction of activated protein C with serpins
    • Hermans JM, Stone SR. Interaction of activated protein C with serpins. Biochem J 1993; 295: 239-45.
    • (1993) Biochem J , vol.295 , pp. 239-245
    • Hermans, J.M.1    Stone, S.R.2
  • 19
    • 0036507774 scopus 로고    scopus 로고
    • Alpha 2-macroglobulin enhances prothrombin activation and thrombin potential by inhibiting the anticoagulant protein C/protein S system in cord and adult plasma
    • Cvirn G, Gallistl S, Koestenberger M et al. Alpha 2-macroglobulin enhances prothrombin activation and thrombin potential by inhibiting the anticoagulant protein C/protein S system in cord and adult plasma. Thromb Res 2002; 105: 433-9.
    • (2002) Thromb Res , vol.105 , pp. 433-439
    • Cvirn, G.1    Gallistl, S.2    Koestenberger, M.3
  • 20
    • 0040778249 scopus 로고    scopus 로고
    • Tracking structural features leading to resistance of activated protein C to alpha 1-antitrypsin
    • Shen L, Dahlback B, Villoutreix BO. Tracking structural features leading to resistance of activated protein C to alpha 1-antitrypsin. Biochemistry 2002; 39: 2853-60.
    • (2002) Biochemistry , vol.39 , pp. 2853-2860
    • Shen, L.1    Dahlback, B.2    Villoutreix, B.O.3
  • 21
    • 0035844272 scopus 로고    scopus 로고
    • Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C
    • Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276: 15567-70.
    • (2001) J Biol Chem , vol.276 , pp. 15567-15570
    • Rezaie, A.R.1
  • 22
    • 80055107829 scopus 로고    scopus 로고
    • Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma
    • Brummel-Ziedins KE, Whelihan MF, Rivard GE et al. Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma. J Thromb Haemost 2011; 9: 2262-7.
    • (2011) J Thromb Haemost , vol.9 , pp. 2262-2267
    • Brummel-Ziedins, K.E.1    Whelihan, M.F.2    Rivard, G.E.3
  • 23
    • 33750058557 scopus 로고    scopus 로고
    • Peptidomimetic inhibitors for activated protein C: implications for hemophilia management
    • Butenas S, Orfeo T, Kalafatis M et al. Peptidomimetic inhibitors for activated protein C: implications for hemophilia management. J Thromb Haemost 2006; 4: 2411-6.
    • (2006) J Thromb Haemost , vol.4 , pp. 2411-2416
    • Butenas, S.1    Orfeo, T.2    Kalafatis, M.3
  • 24
    • 0032521665 scopus 로고    scopus 로고
    • Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function
    • Gal SW, Amontov S, Urvil PT et al. Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function. Eur J Biochem 1998; 252: 553-62.
    • (1998) Eur J Biochem , vol.252 , pp. 553-562
    • Gal, S.W.1    Amontov, S.2    Urvil, P.T.3
  • 25
    • 64749104065 scopus 로고    scopus 로고
    • An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor
    • Müller J, Isermann B, Dücker C et al. An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. Chem Biol 2009; 16: 442-51.
    • (2009) Chem Biol , vol.16 , pp. 442-451
    • Müller, J.1    Isermann, B.2    Dücker, C.3
  • 26
    • 84923112064 scopus 로고    scopus 로고
    • An RNAi therapeutic targeting antithrombin increases thrombin generation and hemostasis. XXIV Congress of ISTH, abstr.
    • Sehgal A, Barros S, Qin J. An RNAi therapeutic targeting antithrombin increases thrombin generation and hemostasis. XXIV Congress of ISTH, 2013; abstr.
    • (2013)
    • Sehgal, A.1    Barros, S.2    Qin, J.3
  • 27
    • 84923076343 scopus 로고    scopus 로고
    • Expanded therapeutic index of antithrombin silencing and correction of APTT in a haemophilia mouse model. 55th Am Soc of Hematol Meeting, abstr.
    • Barros SA, Carioto M, Hettinger J et al. Expanded therapeutic index of antithrombin silencing and correction of APTT in a haemophilia mouse model. 55th Am Soc of Hematol Meeting, 2013; abstr.
    • (2013)
    • Barros, S.A.1    Carioto, M.2    Hettinger, J.3
  • 28
    • 84923112063 scopus 로고    scopus 로고
    • A subcutaneously administered RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim phase 1 study results in healthy volunteers and patients with hemophilia A or B. 56th ASH Meeting, 93 (abstr).
    • Mant T, Akinc A, Simon A et al. A subcutaneously administered RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim phase 1 study results in healthy volunteers and patients with hemophilia A or B. 56th ASH Meeting, 2014; 93 (abstr).
    • (2014)
    • Mant, T.1    Akinc, A.2    Simon, A.3
  • 29
    • 0025819780 scopus 로고
    • Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma
    • Nordfang O, Valentin S, Beck TC et al. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost 1991; 66: 464-7.
    • (1991) Thromb Haemost , vol.66 , pp. 464-467
    • Nordfang, O.1    Valentin, S.2    Beck, T.C.3
  • 30
    • 33645538085 scopus 로고    scopus 로고
    • Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP)
    • Liu T, Scallan CD, Broze GJ Jr et al. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP). Thromb Haemost 2006; 95: 68-76.
    • (2006) Thromb Haemost , vol.95 , pp. 68-76
    • Liu, T.1    Scallan, C.D.2    Broze Jr, G.J.3
  • 31
    • 38349145384 scopus 로고    scopus 로고
    • Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A
    • Prasad S, Lillicrap D, Labelle A et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 2008; 111: 672-9.
    • (2008) Blood , vol.111 , pp. 672-679
    • Prasad, S.1    Lillicrap, D.2    Labelle, A.3
  • 32
    • 84892650393 scopus 로고    scopus 로고
    • Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI)
    • Dockal M, Hartmann R, Fries M et al. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI). J Biol Chem 2014; 289: 1732-41.
    • (2014) J Biol Chem , vol.289 , pp. 1732-1741
    • Dockal, M.1    Hartmann, R.2    Fries, M.3
  • 33
    • 84862499521 scopus 로고    scopus 로고
    • Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model
    • Hilden I, Lauritzen B, Sørensen BB et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012; 119: 5871-8.
    • (2012) Blood , vol.119 , pp. 5871-5878
    • Hilden, I.1    Lauritzen, B.2    Sørensen, B.B.3
  • 34
    • 79956299608 scopus 로고    scopus 로고
    • Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor
    • Waters EK, Genga RM, Schwartz MC et al. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 2011; 117: 5514-22.
    • (2011) Blood , vol.117 , pp. 5514-5522
    • Waters, E.K.1    Genga, R.M.2    Schwartz, M.C.3
  • 35
    • 84870238164 scopus 로고    scopus 로고
    • Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia
    • Gissel M, Orfeo T, Foley JH et al. Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. Thromb Res 2012; 130: 948-55.
    • (2012) Thromb Res , vol.130 , pp. 948-955
    • Gissel, M.1    Orfeo, T.2    Foley, J.H.3
  • 36
    • 84883756006 scopus 로고    scopus 로고
    • Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein
    • Waters EK, Genga RM, Thomson HA et al. Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. Thromb Haemost 2013; 11: 1137-45.
    • (2013) Thromb Haemost , vol.11 , pp. 1137-1145
    • Waters, E.K.1    Genga, R.M.2    Thomson, H.A.3
  • 37
    • 84923087766 scopus 로고    scopus 로고
    • Biological explanation of clinically observed elevation of TFPI plasma levels after treatment with TFPI-antagonistic aptamer BAX 499. 54th Am Society of Hematol Meeting, Abstract 1104.
    • Dockal M, Pachlinger R, Hartmann R et al. Biological explanation of clinically observed elevation of TFPI plasma levels after treatment with TFPI-antagonistic aptamer BAX 499. 54th Am Society of Hematol Meeting, 2012; Abstract 1104.
    • (2012)
    • Dockal, M.1    Pachlinger, R.2    Hartmann, R.3
  • 38
    • 84923093896 scopus 로고    scopus 로고
    • Treatment of hemophilia A and B with BAX 499, an aptamer based specific inhibitor of TFPI - summary data of a clinical phase 1 trial
    • Wong WY, Bevan D, Sorensen B et al. Treatment of hemophilia A and B with BAX 499, an aptamer based specific inhibitor of TFPI - summary data of a clinical phase 1 trial. Haemophilia 2012; 18: 531.
    • (2012) Haemophilia , vol.18 , pp. 531
    • Wong, W.Y.1    Bevan, D.2    Sorensen, B.3
  • 39
    • 84857978849 scopus 로고    scopus 로고
    • Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia
    • Maroney SA, Cooley BC, Ferrel JP et al. Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proc Natl Acad Sci USA 2012; 109: 3927-31.
    • (2012) Proc Natl Acad Sci USA , vol.109 , pp. 3927-3931
    • Maroney, S.A.1    Cooley, B.C.2    Ferrel, J.P.3
  • 40
    • 84923100012 scopus 로고    scopus 로고
    • A TFPI inhibitory half life extended fusion peptide proves efficacy in FVIII knock out mice and marmoset monkeys. 56th ASH Meeting, 1469 (abstr).
    • Dockal M, Hartmann R, Polakowski T et al. A TFPI inhibitory half life extended fusion peptide proves efficacy in FVIII knock out mice and marmoset monkeys. 56th ASH Meeting, 2014; 1469 (abstr).
    • (2014)
    • Dockal, M.1    Hartmann, R.2    Polakowski, T.3
  • 42
    • 39649106357 scopus 로고    scopus 로고
    • Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis
    • Hedner U, Ezban M. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis. Annu Rev Med 2008; 59: 29-41.
    • (2008) Annu Rev Med , vol.59 , pp. 29-41
    • Hedner, U.1    Ezban, M.2
  • 43
    • 0023720558 scopus 로고
    • A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo
    • Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol 1988; 69: 491-7.
    • (1988) Br J Haematol , vol.69 , pp. 491-497
    • Giles, A.R.1    Mann, K.G.2    Nesheim, M.E.3
  • 44
    • 0036908074 scopus 로고    scopus 로고
    • A fully recombinant partial prothrombin complex effectively bypasses fVIII in vitro and in vivo
    • Himmelspach M, Richter G, Muhr E et al. A fully recombinant partial prothrombin complex effectively bypasses fVIII in vitro and in vivo. Thromb Haemost 2002; 88: 1003-11.
    • (2002) Thromb Haemost , vol.88 , pp. 1003-1011
    • Himmelspach, M.1    Richter, G.2    Muhr, E.3
  • 45
    • 0346874351 scopus 로고    scopus 로고
    • A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone
    • Tomokiyo K, Nakatomi Y, Araki T et al. A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone. Vox Sang 2003; 85: 290-9.
    • (2003) Vox Sang , vol.85 , pp. 290-299
    • Tomokiyo, K.1    Nakatomi, Y.2    Araki, T.3
  • 46
    • 0028811109 scopus 로고
    • Procoagulant activity of reversibly acylated human factor Xa
    • Wolf DL, Lin PH, Hollenbach S et al. Procoagulant activity of reversibly acylated human factor Xa. Blood 1995; 86: 4153-7.
    • (1995) Blood , vol.86 , pp. 4153-4157
    • Wolf, D.L.1    Lin, P.H.2    Hollenbach, S.3
  • 47
    • 29244450161 scopus 로고    scopus 로고
    • Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas
    • Louvain-Quintard VB, Bianchini EP, Calmel-Tareau C et al. Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas. J Biol Chem 2005; 280: 41352-9.
    • (2005) J Biol Chem , vol.280 , pp. 41352-41359
    • Louvain-Quintard, V.B.1    Bianchini, E.P.2    Calmel-Tareau, C.3
  • 48
    • 84864111891 scopus 로고    scopus 로고
    • Bioengineered factor Xa as a potential new strategy for hemophilia therapy
    • Camire RM. Bioengineered factor Xa as a potential new strategy for hemophilia therapy. Expert Rev Hematol 2012; 5: 121-3.
    • (2012) Expert Rev Hematol , vol.5 , pp. 121-123
    • Camire, R.M.1
  • 49
    • 78650988916 scopus 로고    scopus 로고
    • Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro
    • Bunce MW, Toso R, Camire RM. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood 2011; 117: 290-8.
    • (2011) Blood , vol.117 , pp. 290-298
    • Bunce, M.W.1    Toso, R.2    Camire, R.M.3
  • 50
    • 80755125572 scopus 로고    scopus 로고
    • A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia
    • Ivanciu L, Toso R, Margaritis P et al. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat Biotechnol 2011; 29: 1028-33.
    • (2011) Nat Biotechnol , vol.29 , pp. 1028-1033
    • Ivanciu, L.1    Toso, R.2    Margaritis, P.3
  • 51
    • 84355162288 scopus 로고    scopus 로고
    • Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - phase I trial
    • Shirahata A, Fukutake K, Mimaya J et al. Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - phase I trial. Haemophilia 2012; 18: 94-101.
    • (2012) Haemophilia , vol.18 , pp. 94-101
    • Shirahata, A.1    Fukutake, K.2    Mimaya, J.3
  • 52
    • 84874092003 scopus 로고    scopus 로고
    • Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors - phase I trial: 2nd report
    • Shirahata A, Fukutake K, Mimaya J et al. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors - phase I trial: 2nd report. Haemophilia 2013; 19: 330-7.
    • (2013) Haemophilia , vol.19 , pp. 330-337
    • Shirahata, A.1    Fukutake, K.2    Mimaya, J.3
  • 53
    • 84886639305 scopus 로고    scopus 로고
    • A phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics
    • Shirahata A, Fukutake K, Takamatsu J et al. A phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics. Haemophilia 2013; 19: 853-60.
    • (2013) Haemophilia , vol.19 , pp. 853-860
    • Shirahata, A.1    Fukutake, K.2    Takamatsu, J.3
  • 54
    • 0036707993 scopus 로고    scopus 로고
    • Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C
    • Gale AJ, Xu X, Pellequer JL et al. Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. Protein Sci 2002; 11: 2091-101.
    • (2002) Protein Sci , vol.11 , pp. 2091-2101
    • Gale, A.J.1    Xu, X.2    Pellequer, J.L.3
  • 55
    • 84896802437 scopus 로고    scopus 로고
    • Improved hemostasis in hemophilia mice by means of an engineered FVa mutant
    • von Drygalski A, Cramer T, Bhat V et al. Improved hemostasis in hemophilia mice by means of an engineered FVa mutant. J Thromb Haemost 2014; 12: 363-72.
    • (2014) J Thromb Haemost , vol.12 , pp. 363-372
    • von Drygalski, A.1    Cramer, T.2    Bhat, V.3
  • 56
    • 85116184768 scopus 로고    scopus 로고
    • superfva and recombinant human FVIIa in vivo suggests a novel bypassing strategy for hemophilia patients with inhibitors. 56th ASH Meeting, 691 (abstr).
    • superfva and recombinant human FVIIa in vivo suggests a novel bypassing strategy for hemophilia patients with inhibitors. 56th ASH Meeting, 2014; 691 (abstr).
    • (2014)
    • Bhat, V.1    von Drygalski, A.2    Gale, A.3
  • 57
    • 84855832171 scopus 로고    scopus 로고
    • Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice
    • Milanov P, Ivanciu L, Abriss D et al. Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice. Blood 2012; 119: 602-11.
    • (2012) Blood , vol.119 , pp. 602-611
    • Milanov, P.1    Ivanciu, L.2    Abriss, D.3
  • 58
    • 34948831582 scopus 로고    scopus 로고
    • A potent erythropoietin-mimicking human antibody interacts through a novel binding site
    • Liu Z, Stoll VS, Devries PJ et al. A potent erythropoietin-mimicking human antibody interacts through a novel binding site. Blood 2007; 110: 2408-13.
    • (2007) Blood , vol.110 , pp. 2408-2413
    • Liu, Z.1    Stoll, V.S.2    Devries, P.J.3
  • 59
    • 84860577150 scopus 로고    scopus 로고
    • A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control
    • Bhaskar V, Goldfine ID, Bedinger DH et al. A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control. Diabetes 2012; 61: 1263-71.
    • (2012) Diabetes , vol.61 , pp. 1263-1271
    • Bhaskar, V.1    Goldfine, I.D.2    Bedinger, D.H.3
  • 60
    • 0037186916 scopus 로고    scopus 로고
    • The prevalence of proteolytic antibodies against factor VIII in hemophilia A
    • Lacroix-Desmazes S, Bayry J, Misra N et al. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med 2002; 346: 662-7.
    • (2002) N Engl J Med , vol.346 , pp. 662-667
    • Lacroix-Desmazes, S.1    Bayry, J.2    Misra, N.3
  • 61
    • 0041880705 scopus 로고    scopus 로고
    • Autoantibodies to factor VIII with catalytic activity
    • Bayry J, Lacroix-Desmazes S, Pashov A et al. Autoantibodies to factor VIII with catalytic activity. Autoimmun Rev 2003; 2: 30-5.
    • (2003) Autoimmun Rev , vol.2 , pp. 30-35
    • Bayry, J.1    Lacroix-Desmazes, S.2    Pashov, A.3
  • 62
    • 4644358187 scopus 로고    scopus 로고
    • An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex
    • Kerschbaumer RJ, Riedrich K, Kral M et al. An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex. J Biol Chem 2004; 279: 40445-50.
    • (2004) J Biol Chem , vol.279 , pp. 40445-40450
    • Kerschbaumer, R.J.1    Riedrich, K.2    Kral, M.3
  • 63
    • 84870302675 scopus 로고    scopus 로고
    • A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
    • Kitazawa T, Igawa T, Sampei Z et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18: 1570-4.
    • (2012) Nat Med , vol.18 , pp. 1570-1574
    • Kitazawa, T.1    Igawa, T.2    Sampei, Z.3
  • 64
    • 84911438456 scopus 로고    scopus 로고
    • The anti-factor IXa/X bispecific antibody ACE910 prevents spontaneous joint bleeds in a long-term primate model of acquired hemophilia A
    • Muto A, Yoshihashi K, Takeda M et al. The anti-factor IXa/X bispecific antibody ACE910 prevents spontaneous joint bleeds in a long-term primate model of acquired hemophilia A. Blood 2014; 124: 3165-71.
    • (2014) Blood , vol.124 , pp. 3165-3171
    • Muto, A.1    Yoshihashi, K.2    Takeda, M.3
  • 65
    • 84893537691 scopus 로고    scopus 로고
    • Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation
    • Muto A, Yoshihashi K, Takeda M et al. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost 2013; 12: 206-13.
    • (2013) J Thromb Haemost , vol.12 , pp. 206-213
    • Muto, A.1    Yoshihashi, K.2    Takeda, M.3
  • 66
    • 84923072168 scopus 로고    scopus 로고
    • The safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function, demonstrated in healthy adults
    • Shima M, Uchida N, Sanbe T et al. The safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function, demonstrated in healthy adults. Haemophilia 2014; 20: 76.
    • (2014) Haemophilia , vol.20 , pp. 76
    • Shima, M.1    Uchida, N.2    Sanbe, T.3
  • 67
    • 84923076342 scopus 로고    scopus 로고
    • Safety and prophylactic efficacy profiles of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function, in Japanese hemophilia A patients both without and with FVIII Inhibitors: first-in-patient phase 1 study. 56th ASH Meeting, 691 (abstr).
    • Shima M, Hanabusa H, Taki M et al. Safety and prophylactic efficacy profiles of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function, in Japanese hemophilia A patients both without and with FVIII Inhibitors: first-in-patient phase 1 study. 56th ASH Meeting, 2014; 691 (abstr).
    • (2014)
    • Shima, M.1    Hanabusa, H.2    Taki, M.3
  • 68
    • 84893573623 scopus 로고    scopus 로고
    • FXIII - mechanisms of action in the treatment of hemophilia A
    • Rea CJ, Foley JH, Okaisabor O et al. FXIII - mechanisms of action in the treatment of hemophilia A. J Thromb Haemost 2014; 12: 159-68.
    • (2014) J Thromb Haemost , vol.12 , pp. 159-168
    • Rea, C.J.1    Foley, J.H.2    Okaisabor, O.3
  • 69
    • 79952065857 scopus 로고    scopus 로고
    • Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A
    • Rea CJ, Foley JH, Ingerslev J et al. Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A. J Thromb Haemost 2011; 9: 510-6.
    • (2011) J Thromb Haemost , vol.9 , pp. 510-516
    • Rea, C.J.1    Foley, J.H.2    Ingerslev, J.3
  • 70
    • 0041965943 scopus 로고    scopus 로고
    • Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A
    • Hrachovinová I, Cambien B, Hafezi-Moghadam A et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 2003; 9: 1020-5.
    • (2003) Nat Med , vol.9 , pp. 1020-1025
    • Hrachovinová, I.1    Cambien, B.2    Hafezi-Moghadam, A.3
  • 71
    • 0035997219 scopus 로고    scopus 로고
    • Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system
    • Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med (Berl) 2002; 80: 367-76.
    • (2002) J Mol Med (Berl) , vol.80 , pp. 367-376
    • Keeling, K.M.1    Bedwell, D.M.2
  • 72
    • 77956311645 scopus 로고    scopus 로고
    • Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124)
    • Finkel RS. Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol 2010; 25: 1158-64.
    • (2010) J Child Neurol , vol.25 , pp. 1158-1164
    • Finkel, R.S.1
  • 73
    • 27644488290 scopus 로고    scopus 로고
    • Aminoglycoside suppression of nonsense mutations in severe hemophilia
    • James PD, Raut S, Rivard GE et al. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood 2005; 106: 3043-8.
    • (2005) Blood , vol.106 , pp. 3043-3048
    • James, P.D.1    Raut, S.2    Rivard, G.E.3
  • 74
    • 78649462808 scopus 로고    scopus 로고
    • Nonsense suppression approaches in treating hemophilia
    • 512 (Abstract)
    • Liu Y-L, Margaritis P, Khazi F et al. Nonsense suppression approaches in treating hemophilia. Blood 2008; 112: 512 (Abstract)
    • (2008) Blood , vol.112
    • Liu, Y.-L.1    Margaritis, P.2    Khazi, F.3
  • 75
    • 0033525169 scopus 로고    scopus 로고
    • A perfect message: RNA surveillance and nonsense-mediated decay
    • Hentze MW, Kulozik AE. A perfect message: RNA surveillance and nonsense-mediated decay. Cell 1999; 96: 307-10.
    • (1999) Cell , vol.96 , pp. 307-310
    • Hentze, M.W.1    Kulozik, A.E.2
  • 76
    • 0033846632 scopus 로고    scopus 로고
    • Epsilon-aminocaproic acid inhibits the activity of factor VIII inhibitors in patients with severe haemophilia A in vivo and in vitro
    • Ghosh K, Shetty S, Pathare A et al. Epsilon-aminocaproic acid inhibits the activity of factor VIII inhibitors in patients with severe haemophilia A in vivo and in vitro. Acta Haematol 2000; 103: 67-72.
    • (2000) Acta Haematol , vol.103 , pp. 67-72
    • Ghosh, K.1    Shetty, S.2    Pathare, A.3
  • 77
    • 1042304227 scopus 로고    scopus 로고
    • Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors
    • Ghosh K, Shetty S, Jijina F et al. Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors. Haemophilia 2004; 10: 58-62.
    • (2004) Haemophilia , vol.10 , pp. 58-62
    • Ghosh, K.1    Shetty, S.2    Jijina, F.3
  • 78
    • 84923092537 scopus 로고    scopus 로고
    • Nanobody-based TAFIa stabilization stabilizes hemophilia A clots and reduces the bleeding tendency in mice
    • Hendrickx M, Declerck P, Mosnier L. Nanobody-based TAFIa stabilization stabilizes hemophilia A clots and reduces the bleeding tendency in mice. Haemophilia 2014; 20: 79.
    • (2014) Haemophilia , vol.20 , pp. 79
    • Hendrickx, M.1    Declerck, P.2    Mosnier, L.3
  • 79
    • 84923087765 scopus 로고    scopus 로고
    • Prevention of premature fibrinolysis and reduction of bleeding in vivo in hemophilia with inhibitors by a stabilized TAFI variant. 56th ASH Meeting, 694 (abstr).
    • Hendrickx M, Bhat V, Gills A et al. Prevention of premature fibrinolysis and reduction of bleeding in vivo in hemophilia with inhibitors by a stabilized TAFI variant. 56th ASH Meeting, 2014; 694 (abstr).
    • (2014)
    • Hendrickx, M.1    Bhat, V.2    Gills, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.